Physician

Todd David Daugherty, M.D.

According to 2025 Medicare claims, Todd Daugherty, M.D. (NPI: 1639390776) practices rheumatology in the Manchester-Nashua, NH market, with the plurality of this provider's patient population coming from Hillsborough, NH. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES -NH PLLC (NPI: 1871132019; TIN: 844094465) and primary practice location at 03242-3506. Daugherty is affiliated with the MaineHealth Accountable Care Organization (ACO ID: A1290), Concord Hospital ACO, LLC (ACO ID: A4984), Aledade 205 New England MSSP Enhanced (ACO ID: A5370), Dartmouth Health Performance Network, LLC (ACO ID: A5414), Aledade 201 National MSSP (ACO ID: A5522), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Daugherty's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 119 traditional Medicare patients, billed 93,347 HCPCS/CPT codes, and received $1,402,834 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 752 prescription claims across 118 beneficiaries totaling $292,774 in drug costs, led by Xeljanz Xr (Tofacitinib Citrate). Open Payments data shows 88 records totaling $4,352. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $74,609 to $1,402,834. In contrast, Part D prescription costs have moved from a higher plateau to a lower plateau, from $864,350 to $292,774. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	604	1,337	$74,609
2016	419	943	$60,135
2017	267	780	$59,515
2018	220	871	$53,548
2019	220	949	$73,516
2020	174	21,714	$815,575
2021	112	41,048	$1,292,229
2022	102	68,734	$1,578,526
2023	97	95,373	$1,952,916
2024	119	93,347	$1,402,834

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	368	2,655	$864,350
2016	339	1,816	$1,000,509
2017	213	1,344	$613,326
2018	197	1,497	$1,030,470
2019	207	1,558	$1,031,968
2020	185	1,340	$716,350
2021	125	958	$226,982
2022	111	832	$320,930
2023	108	817	$371,632
2024	118	752	$292,774

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	26	26	$176
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	102	273	$147
96413	Administration of chemotherapy into vein, 1 hour or less	58	443	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	46	70	$104
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	71	138	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xeljanz Xr	Tofacitinib Citrate	13	390	$87,331
Humira(Cf) Pen	Adalimumab	12	336	$81,641
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	208	18,395	$12,230
Leflunomide	Leflunomide	116	10,520	$10,915
Sulfasalazine Dr	Sulfasalazine	69	6,004	$7,605

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	88	$4,352	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Todd David Daugherty, M.D.?

Tedicare shows public-source Medicare data for Todd David Daugherty, M.D. (NPI 1639390776), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Todd David Daugherty, M.D. have ACO affiliation data?

Todd David Daugherty, M.D. is shown with ACO affiliation data for MaineHealth Accountable Care Organization (MSSP, ACO ID A1290), Concord Hospital ACO, LLC (MSSP, ACO ID A4984), Aledade 205 New England MSSP Enhanced (MSSP, ACO ID A5370), Dartmouth Health Performance Network, LLC (MSSP, ACO ID A5414), Aledade 201 National MSSP (MSSP, ACO ID A5522), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Todd David Daugherty, M.D.?

Todd David Daugherty, M.D. is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES -NH PLLC (billing NPI 1871132019) in the available physician profile data.

Does Todd David Daugherty, M.D. have Open Payments data?

Todd David Daugherty, M.D. has 88 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.